Alethia Young
Stock Analyst at Cantor Fitzgerald
(2.93)
# 1,452
Out of 5,140 analysts
137
Total ratings
53.64%
Success rate
31.05%
Average return
Main Sectors:
Stocks Rated by Alethia Young
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RCUS Arcus Biosciences | Reiterates: Overweight | n/a | $22.95 | - | 5 | Jul 5, 2024 | |
| ARWR Arrowhead Pharmaceuticals | Reiterates: Overweight | n/a | $67.60 | - | 5 | Jun 20, 2024 | |
| REGN Regeneron Pharmaceuticals | Maintains: Neutral | $800 → $850 | $749.33 | +13.43% | 9 | Oct 16, 2023 | |
| ALXO ALX Oncology Holdings | Reiterates: Overweight | $18 | $1.47 | +1,124.49% | 6 | Sep 12, 2023 | |
| CRIS Curis | Reiterates: Overweight | $60 | $0.90 | +6,603.91% | 3 | Sep 7, 2023 | |
| ELDN Eledon Pharmaceuticals | Reiterates: Overweight | $9 | $2.20 | +309.09% | 2 | Aug 22, 2023 | |
| VSTM Verastem | Reiterates: Overweight | $34 | $6.36 | +434.59% | 2 | Jul 6, 2023 | |
| BIIB Biogen | Maintains: Neutral | $427 → $327 | $172.62 | +89.43% | 7 | Oct 15, 2021 | |
| RAPT RAPT Therapeutics | Maintains: Overweight | $408 → $568 | $57.61 | +885.94% | 2 | Jun 14, 2021 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $285 → $281 | $461.14 | -39.06% | 5 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $8 | $1.37 | +483.94% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $86 → $98 | $1.18 | +8,205.08% | 3 | Feb 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $280 → $295 | $343.60 | -14.14% | 9 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $84 → $86 | $129.11 | -33.39% | 3 | Oct 29, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $48 | $31.57 | +52.04% | 4 | Oct 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $6.90 | +334.78% | 1 | Oct 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $70 → $72 | $27.17 | +165.00% | 8 | Jul 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $5 | $2.42 | +106.61% | 5 | Jun 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $83 → $100 | $104.67 | -4.46% | 6 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $185 → $201 | $216.66 | -7.23% | 6 | Apr 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $86 → $85 | $75.56 | +12.49% | 5 | Apr 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $30 → $32 | $14.78 | +116.51% | 1 | Mar 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $211 → $217 | $21.37 | +915.44% | 12 | Feb 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $75 → $48 | $46.68 | +2.83% | 4 | Oct 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | n/a | $17.36 | - | 3 | Mar 22, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $151 → $154 | $365.46 | -57.86% | 5 | Mar 13, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $113 → $116 | $56.77 | +104.33% | 2 | Mar 2, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $147 → $106 | $6.89 | +1,438.46% | 8 | Jan 24, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $28 | $14.03 | +99.57% | 1 | Nov 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $85 → $82 | $207.34 | -60.45% | 2 | Sep 27, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Underperform | n/a | $469.77 | - | 1 | Mar 16, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $3.40 | - | 1 | Oct 18, 2016 |
Arcus Biosciences
Jul 5, 2024
Reiterates: Overweight
Price Target: n/a
Current: $22.95
Upside: -
Arrowhead Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $67.60
Upside: -
Regeneron Pharmaceuticals
Oct 16, 2023
Maintains: Neutral
Price Target: $800 → $850
Current: $749.33
Upside: +13.43%
ALX Oncology Holdings
Sep 12, 2023
Reiterates: Overweight
Price Target: $18
Current: $1.47
Upside: +1,124.49%
Curis
Sep 7, 2023
Reiterates: Overweight
Price Target: $60
Current: $0.90
Upside: +6,603.91%
Eledon Pharmaceuticals
Aug 22, 2023
Reiterates: Overweight
Price Target: $9
Current: $2.20
Upside: +309.09%
Verastem
Jul 6, 2023
Reiterates: Overweight
Price Target: $34
Current: $6.36
Upside: +434.59%
Biogen
Oct 15, 2021
Maintains: Neutral
Price Target: $427 → $327
Current: $172.62
Upside: +89.43%
RAPT Therapeutics
Jun 14, 2021
Maintains: Overweight
Price Target: $408 → $568
Current: $57.61
Upside: +885.94%
Vertex Pharmaceuticals
Jun 11, 2021
Maintains: Overweight
Price Target: $285 → $281
Current: $461.14
Upside: -39.06%
Mar 8, 2021
Initiates: Overweight
Price Target: $8
Current: $1.37
Upside: +483.94%
Feb 25, 2021
Maintains: Overweight
Price Target: $86 → $98
Current: $1.18
Upside: +8,205.08%
Feb 3, 2021
Maintains: Overweight
Price Target: $280 → $295
Current: $343.60
Upside: -14.14%
Oct 29, 2020
Reiterates: Overweight
Price Target: $84 → $86
Current: $129.11
Upside: -33.39%
Oct 28, 2020
Maintains: Overweight
Price Target: $30 → $48
Current: $31.57
Upside: +52.04%
Oct 12, 2020
Initiates: Overweight
Price Target: $30
Current: $6.90
Upside: +334.78%
Jul 31, 2020
Maintains: Overweight
Price Target: $70 → $72
Current: $27.17
Upside: +165.00%
Jun 2, 2020
Assumes: Overweight
Price Target: $5
Current: $2.42
Upside: +106.61%
May 19, 2020
Maintains: Neutral
Price Target: $83 → $100
Current: $104.67
Upside: -4.46%
Apr 20, 2020
Reiterates: Overweight
Price Target: $185 → $201
Current: $216.66
Upside: -7.23%
Apr 8, 2020
Reiterates: Overweight
Price Target: $86 → $85
Current: $75.56
Upside: +12.49%
Mar 6, 2020
Maintains: Overweight
Price Target: $30 → $32
Current: $14.78
Upside: +116.51%
Feb 27, 2020
Reiterates: Overweight
Price Target: $211 → $217
Current: $21.37
Upside: +915.44%
Oct 3, 2019
Maintains: Neutral
Price Target: $75 → $48
Current: $46.68
Upside: +2.83%
Mar 22, 2018
Downgrades: Underperform
Price Target: n/a
Current: $17.36
Upside: -
Mar 13, 2018
Maintains: Outperform
Price Target: $151 → $154
Current: $365.46
Upside: -57.86%
Mar 2, 2018
Maintains: Outperform
Price Target: $113 → $116
Current: $56.77
Upside: +104.33%
Jan 24, 2018
Maintains: Outperform
Price Target: $147 → $106
Current: $6.89
Upside: +1,438.46%
Nov 3, 2017
Maintains: Outperform
Price Target: $24 → $28
Current: $14.03
Upside: +99.57%
Sep 27, 2017
Maintains: Neutral
Price Target: $85 → $82
Current: $207.34
Upside: -60.45%
Mar 16, 2017
Initiates: Underperform
Price Target: n/a
Current: $469.77
Upside: -
Oct 18, 2016
Initiates: Outperform
Price Target: n/a
Current: $3.40
Upside: -